



Edgar Filing: vTv Therapeutics Inc. - Form 8-K

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

---

Item 8.01 Other Events

On December 14, 2016, vTv Therapeutics Inc. issued a press release announcing positive data from its Phase 2 study evaluating TTP273, an oral small molecule GLP-1R agonist, for the treatment of Type 2 diabetes.

Through the Phase 2 study, TTP273 demonstrated a statistically significant reduction in HbA1c. The compound was well-tolerated, with negligible incidences of nausea and vomiting across all arms of the study. Trends toward weight loss were also observed.

A copy of the press release is attached as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.	Description
99.1	Press Release dated December 14, 2016

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

VTV THERAPEUTICS INC.

By: /s/ Rudy C. Howard  
Name: Rudy C. Howard  
Title: Chief Financial Officer

Dated: December 15, 2016

3